- Home
- MGNI vs AMRX Comparison
MGNI vs AMRX Comparison
Compare MGNI & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- AMRX
- Stock Information
- Founded
- MGNI 2007
- AMRX 2002
- Country
- MGNI United States
- AMRX United States
- Employees
- MGNI N/A
- AMRX N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- AMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- AMRX Health Care
- Exchange
- MGNI Nasdaq
- AMRX Nasdaq
- Market Cap
- MGNI 3.1B
- AMRX 3.3B
- IPO Year
- MGNI N/A
- AMRX N/A
- Fundamental
- Price
- MGNI $18.68
- AMRX $10.20
- Analyst Decision
- MGNI Strong Buy
- AMRX Strong Buy
- Analyst Count
- MGNI 11
- AMRX 4
- Target Price
- MGNI $26.18
- AMRX $12.00
- AVG Volume (30 Days)
- MGNI 3.1M
- AMRX 1.7M
- Earning Date
- MGNI 11-05-2025
- AMRX 10-30-2025
- Dividend Yield
- MGNI N/A
- AMRX N/A
- EPS Growth
- MGNI N/A
- AMRX N/A
- EPS
- MGNI 0.29
- AMRX 0.01
- Revenue
- MGNI $685,074,000.00
- AMRX $2,852,914,000.00
- Revenue This Year
- MGNI $2.09
- AMRX $9.52
- Revenue Next Year
- MGNI $11.41
- AMRX $6.31
- P/E Ratio
- MGNI $66.93
- AMRX $965.99
- Revenue Growth
- MGNI 5.52
- AMRX 9.81
- 52 Week Low
- MGNI $8.22
- AMRX $6.69
- 52 Week High
- MGNI $26.65
- AMRX $10.68
- Technical
- Relative Strength Index (RSI)
- MGNI 29.78
- AMRX 58.10
- Support Level
- MGNI $18.67
- AMRX $10.35
- Resistance Level
- MGNI $20.79
- AMRX $10.61
- Average True Range (ATR)
- MGNI 1.06
- AMRX 0.27
- MACD
- MGNI -0.45
- AMRX 0.01
- Stochastic Oscillator
- MGNI 5.93
- AMRX 62.63
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.